Preferred Label : Gilteritinib Fumarate;
NCIt synonyms : 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-,
(2E)-2-Butenedioate (2:1); Gilteritinib Hemifumarate;
NCIt definition : The fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor
tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11),
anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK),
with potential antineoplastic activity. Upon administration, gilteritinib binds to
and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This
may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction
pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3,
AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell
types, play key roles in tumor cell growth and survival.;
UNII : 5RZZ0Z1GJT;
InChIKey : UJOUWHLYTQFUCU-WXXKFALUSA-N;
CAS number : 1254053-84-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1254053-84-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Xospata;
Molecule name : ASP-2215 Hemifumarate;
Origin ID : C119665;
UMLS CUI : C3896946;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_component_of_chemotherapy_regimen
- is_salt_form_of
